Hansoh
Hansoh
Haosen Pharmaceuticals has developed into a modern and innovative pharmaceutical group integrating chemical and biological drug research
Haosen Pharmaceuticals has developed into a modern and innovative pharmaceutical group integrating chemical and biological drug research, pharmaceutical intermediates and API synthesis, preparation manufacturing and product sales. It is a national key high-tech enterprise, one of the top 20 of China's top 100 pharmaceutical enterprises, and one of the main R&D and production bases of anti-tumor and psychotropic drugs in China.
- All
- News
- Analysis
- Research
Briefing Feb 16, 2023 12:51 PM
· Healthcare
Innovative Drug Developer Rezu Bio Raised CNY 10 Mn in Series Pre-A
Briefing Feb 07, 2023 12:11 PM
· Healthcare
ForLong Biotech Nets Over CNY 100 Mn in Series A
In-depth
Briefing Feb 07, 2023 10:59 AM
· Healthcare
CytoCan Corp. Nets CNY 10 Mn in Seed Round
Briefing Jan 30, 2023 10:44 AM
· Healthcare
Levostar Completes Pre-A Financing Round to Further Invest in CGT
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 22, 2021 03:11 PM
Briefing Jan 18, 2023 10:59 AM
· Healthcare
BlissBio Nets Over CNY 100 Mn in Series B+
Briefing Sep 21, 2022 10:38 AM
· Healthcare
Weiyou Gene Nets Tens of Millions of CNY in Series Pre-A Round
Briefing Sep 16, 2022 11:10 PM
· Healthcare
NaviSeed Nets Tens of millions of CNY in Angel Round
Briefing Sep 13, 2022 05:30 PM
· Healthcare
Nuwacell Nets Hundreds of Mns of CNY in Series A
Healthcare
China's First Modified New Drug of Docetaxel Successfully Went to the US
Feb 19, 2025 10:41 AM
Briefing Aug 31, 2022 08:30 PM
· Healthcare
Enitiatebio Nets One Hundred Million of CNY in Series A Round
Briefing Jun 28, 2022 09:56 AM
· Healthcare
And platinum medicine b7h4x4-1bb bispecific antibody were approved by FDA for new drug research
Briefing Jun 28, 2022 09:54 AM
· Healthcare
Fosun pharma and Amgen have reached cooperation to accelerate the commercialization of two innovative drugs in China
Briefing Jun 28, 2022 09:50 AM
· Healthcare
It is expected to achieve functional cure of chronic hepatitis B! GSK antisense therapy phase IIB positive clinical results
Briefing Jun 28, 2022 09:37 AM
· Healthcare
Aibo biology: cooperate with Jiahe biology to jointly develop tumor mRNA drugs
Briefing Jun 24, 2022 11:15 AM
· Healthcare
F-star to be acquired by China biopharmaceutical with USD 161million
Briefing Jun 24, 2022 11:07 AM
· Healthcare
"Delisting warning" of Whitson pharmaceuticals on the New York Stock Exchange
See more
Related Companies
EqualOcean Analysis
- EqualOcean | Southern Weekly 2022 'China Greenwashing List'
- EqualOcean｜China's Top 20 ESG Performers Among Private Enterprises（Part III）
- 20 Chinese Companies to Watch in Q1 2023– Healthcare+
- Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis
- Opportunities and Challenges Hidden in the CGT Industry in China